Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 1, 1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Frontiers in Neurology|August 12, 2022
Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay PlatformStephen Lee, Tatiana Plavina, Carol M Singh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Neurofilament light levels are associated with long-term outcomes in multiple sclerosisJens Kuhle, Tatiana Plavina, Christian Barro, et al.
Annals of Neurology|August 26, 2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick, Paul W O'Connor, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoringPeter A Calabresi, Douglas L Arnold, Dipen Sangurdekar, et al.
The Lancet. Neurology|August 26, 2018
Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective studyBruce D Trapp, Megan Vignos, Jessica Dudman, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 5, 2021
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHSCarrie M Hersh, Bernd Kieseier, Carl de Moor, et al.
JAMA Network Open|November 5, 2020
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis EpisodeTatiana Plavina, Carol M Singh, Dipen Sangurdekar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2005
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosisRobert M Herndon, Richard A Rudick, Frederick E Munschauer, et al.
Pageof 19